Aeterna Zentaris Files Form 6-K

TL;DR

Aeterna Zentaris filed a 6-K on Aug 6, 2024, confirming its foreign private issuer status and 20-F reporting.

AI Summary

On August 6, 2024, Aeterna Zentaris Inc. filed a Form 6-K, reporting on events for the month of August 2024. The filing indicates the company is a foreign private issuer and files annual reports under Form 20-F. The company's principal executive office is located in Toronto, Ontario, Canada.

Why It Matters

This filing provides an update on Aeterna Zentaris Inc.'s regulatory reporting status and corporate information as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine regulatory update and does not contain significant financial or operational news.

Key Players & Entities

• Aeterna Zentaris Inc. (company) — Registrant
• August 6, 2024 (date) — Filing date
• Form 6-K (document) — Filing type
• Form 20-F (document) — Annual report form
• Toronto, Ontario, Canada (location) — Principal executive office location

FAQ

Filing Documents

• form6-k.htm (6-K) — 36KB
• ex99-1.htm (EX-99.1) — 16KB
• ex99-2.htm (EX-99.2) — 2KB
• ex99-3.htm (EX-99.3) — 2KB
• ex99-4.htm (EX-99.4) — 31KB
• ex99-1_001.jpg (GRAPHIC) — 19KB
• ex99-1_012.jpg (GRAPHIC) — 30KB
• ex99-2_001.jpg (GRAPHIC) — 415KB
• ex99-2_002.jpg (GRAPHIC) — 39KB
• ex99-3_001.jpg (GRAPHIC) — 173KB
• ex99-3_002.jpg (GRAPHIC) — 218KB
• 0001493152-24-030454.txt ( ) — 1320KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE Ai-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-38064 Aeterna Zentaris Inc. (Translation of registrant’s name into English) c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): On August 6, 2024, Aeterna Zentaris Inc. (“Aeterna”, “we”, “our” or the “Company”) issued a news release announcing that, effective as of August 6, 2024, its name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.” Effective as of August 9, 2024, the Company’s common shares (the “Common Shares”) will begin trading on the Toronto Stock Exchange (the “TSX”) and NASDAQ Capital Market (the “NASDAQ”) under the trading symbol “CSCI” and will concurrently cease trading thereon under the former trading symbol “AEZS”. A copy of the news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Also on August 6, 2024, the Company filed with the Canadian Securities Administrators on SEDAR+ a material change report relating to the name change, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference. On the same date, the Company also filed on SEDAR+ a certificate of amendment filed under the Canada Business Corporations Act on August 6, 2024 effecting the name change, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference. On the same date, the Company also filed on SEDAR+ the first supplemental indenture by and between the Company and Computershare Trust Company of Canada, governing the terms of the Company’s common share purchase warrants issued in connection with the Company’s business combination with Ceapro, Inc., a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. Exhibit 99.1, 99.3 and 99.4 included with this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561, No. 333-200834 and No. 333-279844) (collectively, the “Registration Statements”) and shall be deemed to be a part thereof from the date on which this Report on Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. The information contained on any websites referenced in Exhibit 99.1 included with this Report on Form 6-K is not incorporated by reference or deemed to be a part of this Report on Form 6-K or any of the Registration Forward-Looking The information in this Report on Form 6-K and the exhibit attached hereto and incorporated herein by reference include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s ability to raise capital and obtain financing to continue its currently planned operations; the Company’s ability to maintain compliance with the continued listing requirements of the NASDAQ and to maintain the listing of its common shares on the NASDAQ; the Company’s ability to continue as a going concern, which is dependent, in part, on its ability to transfer cash from Aeterna Zentaris GmbH to the Company and its U.S. subsidiary and to secure additional financing; the Company’s now heavy dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including its heavy reliance on the

View Full Filing

View this 6-K filing on SEC EDGAR